Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial

Authors

Daniel J George, Duke University
Colin Hessel, Exelixis, Inc.
Susan Halabi, Duke University
M Dror Michaelson, Massachusetts General Hospital Cancer Center
Olwen Hahn, Alliance Protocol Operations Office
Meghara Walsh, Dana-Farber/Partners CancerCare
Joel Picus, Washington University School of Medicine in St. Louis
Eric J Small, UCSF Helen Diller Family Comprehensive Cancer Center
Shaker Dakhil, University of Kansas
Darren R Feldman, Memorial Sloan Kettering Cancer Center
Milan Mangeshkar, Exelixis, Inc.
Christian Scheffold, Exelixis, Inc.
Michael J Morris, Memorial Sloan Kettering Cancer Center
Toni K Choueiri, Dana-Farber/Partners CancerCare

Journal

The oncologist

Publication Date

11-1-2019

Volume

24

Issue

11

First Page

1497

Last Page

1501

Document Type

Open Access Publication

DOI

10.1634/theoncologist.2019-0316

Rights and Permissions

Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri, Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial, The Oncologist, Volume 24, Issue 11, November 2019, Pages 1497–1501, doi.org/10.1634/theoncologist.2019-0316 © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Recommended Citation

George, Daniel J; Hessel, Colin; Halabi, Susan; Michaelson, M Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J; Dakhil, Shaker; Feldman, Darren R; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J; and Choueiri, Toni K, "Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial." The oncologist. 24, 11. 1497 - 1501. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11894